CanSino Biologics (HKG:6185) initiated the phase 1 clinical trial of its inhaled tuberculosis vaccine in Indonesia recently and the first patient has been enrolled, a Thursday Hong Kong bourse filing said.
The phase Ia and Ib trials for the vaccine were completed in Canada, with data demonstrating its safety and its effectiveness as a Bacillus Calmette-Guerin booster vaccine.
Bacillus Calmette-Guerin is reportedly the only available tuberculosis vaccine in the world currently.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.